End-of-day quote
Korea S.E.
06:00:00 2024-05-13 pm EDT
|
5-day change
|
1st Jan Change
|
575
KRW
|
+2.68%
|
|
+2.86%
|
-22.19%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
66,805
|
42,354
|
37,005
|
44,586
|
33,160
|
37,097
|
Enterprise Value (EV)
1 |
33,924
|
64,638
|
58,130
|
37,169
|
25,245
|
41,059
|
P/E ratio
|
-16.1
x
|
-5.59
x
|
-1.4
x
|
-7.48
x
|
-5.28
x
|
-11.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.82
x
|
0.54
x
|
0.85
x
|
3
x
|
3.28
x
|
1.64
x
|
EV / Revenue
|
1.94
x
|
0.82
x
|
1.33
x
|
2.5
x
|
2.5
x
|
1.82
x
|
EV / EBITDA
|
77.6
x
|
-9.47
x
|
-2.18
x
|
7.92
x
|
-4.08
x
|
-5.94
x
|
EV / FCF
|
29.7
x
|
-1.27
x
|
11.1
x
|
1.36
x
|
-2.23
x
|
-6.67
x
|
FCF Yield
|
3.37%
|
-78.5%
|
8.98%
|
73.6%
|
-44.9%
|
-15%
|
Price to Book
|
1.4
x
|
0.84
x
|
1.3
x
|
1.72
x
|
1.41
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
25,115
|
29,515
|
36,458
|
39,111
|
39,196
|
50,198
|
Reference price
2 |
2,660
|
1,435
|
1,015
|
1,140
|
846.0
|
739.0
|
Announcement Date
|
3/19/19
|
3/25/20
|
3/22/21
|
3/18/22
|
3/22/23
|
3/21/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
17,511
|
78,369
|
43,686
|
14,874
|
10,107
|
22,559
|
EBITDA
1 |
437.2
|
-6,822
|
-26,662
|
4,695
|
-6,186
|
-6,910
|
EBIT
1 |
-309.7
|
-9,125
|
-29,854
|
2,900
|
-6,697
|
-7,537
|
Operating Margin
|
-1.77%
|
-11.64%
|
-68.34%
|
19.5%
|
-66.27%
|
-33.41%
|
Earnings before Tax (EBT)
1 |
-3,942
|
-10,932
|
-31,994
|
-2,883
|
-6,510
|
-3,467
|
Net income
1 |
-3,831
|
-7,114
|
-25,031
|
-5,785
|
-6,385
|
-3,296
|
Net margin
|
-21.88%
|
-9.08%
|
-57.3%
|
-38.9%
|
-63.18%
|
-14.61%
|
EPS
2 |
-165.3
|
-256.7
|
-727.5
|
-152.5
|
-160.3
|
-66.00
|
Free Cash Flow
1 |
1,144
|
-50,768
|
5,219
|
27,360
|
-11,329
|
-6,160
|
FCF margin
|
6.53%
|
-64.78%
|
11.95%
|
183.95%
|
-112.09%
|
-27.31%
|
FCF Conversion (EBITDA)
|
261.61%
|
-
|
-
|
582.76%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/19
|
3/25/20
|
3/22/21
|
3/18/22
|
3/22/23
|
3/21/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
22,285
|
21,126
|
-
|
-
|
3,962
|
Net Cash position
1 |
32,881
|
-
|
-
|
7,417
|
7,915
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-3.267
x
|
-0.7923
x
|
-
|
-
|
-0.5734
x
|
Free Cash Flow
1 |
1,144
|
-50,768
|
5,219
|
27,360
|
-11,329
|
-6,160
|
ROE (net income / shareholders' equity)
|
-9.15%
|
-14.1%
|
-67.5%
|
-9.38%
|
-22.8%
|
-11.6%
|
ROA (Net income/ Total Assets)
|
-0.38%
|
-6.27%
|
-17.1%
|
2.63%
|
-10.9%
|
-12.5%
|
Assets
1 |
999,808
|
113,493
|
146,609
|
-220,090
|
58,451
|
26,434
|
Book Value Per Share
2 |
1,905
|
1,717
|
780.0
|
663.0
|
601.0
|
536.0
|
Cash Flow per Share
2 |
299.0
|
413.0
|
232.0
|
190.0
|
270.0
|
49.60
|
Capex
1 |
1,028
|
347
|
207
|
3,951
|
109
|
2,050
|
Capex / Sales
|
5.87%
|
0.44%
|
0.47%
|
26.57%
|
1.08%
|
9.08%
|
Announcement Date
|
3/19/19
|
3/25/20
|
3/22/21
|
3/18/22
|
3/22/23
|
3/21/24
|
|
1st Jan change
|
Capi.
|
---|
| -22.19% | 21.33M | | -20.84% | 12.31B | | -24.53% | 6.59B | | +12.51% | 6.3B | | -8.87% | 5.88B | | -1.75% | 4.74B | | +60.03% | 4.7B | | -4.98% | 4.03B | | -8.76% | 3.58B | | -7.32% | 3.07B |
Other Drug Retailers
|